Canagliflozin: a novel treatment option for type 2 diabetes. - Wikidata - awgldk - TriplyDB

Canagliflozin: a novel treatment option for type 2 diabetes.

Canagliflozin: a novel treatment option for type 2 diabetes.

http://www.wikidata.org/entity/Q34388544

about

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action Targeting metabolic disorders by natural products.Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.Short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting.Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use

P2860

Q27027105-1ADB429F-AD1F-4A8F-945D-9E4C046301B2 Q35830892-F40D02FF-0BD3-4D07-A731-60855D3DBB47 Q38663903-51D9E19B-0FB5-4754-B5B7-E38A80840442 Q50096157-AD0ABAB0-BD4D-4568-B6B2-69D5876DE27A Q57814883-B7FCBA87-9D3E-4D9A-9A7E-D926460E0CD6

P2860

Canagliflozin: a novel treatment option for type 2 diabetes.

http://www.wikidata.org/entity/Q34388544

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Canagliflozin: a novel treatment option for type 2 diabetes.

@ast

Canagliflozin: a novel treatment option for type 2 diabetes.

@en

Canagliflozin: a novel treatment option for type 2 diabetes.

@nl

type

label

Canagliflozin: a novel treatment option for type 2 diabetes.

@ast

Canagliflozin: a novel treatment option for type 2 diabetes.

@en

Canagliflozin: a novel treatment option for type 2 diabetes.

@nl

prefLabel

Canagliflozin: a novel treatment option for type 2 diabetes.

@ast

Canagliflozin: a novel treatment option for type 2 diabetes.

@en

Canagliflozin: a novel treatment option for type 2 diabetes.

@nl

P1433

Q34388544-48750C05-A46B-4639-BB7F-6367BC82259B

P1476

Q34388544-378C8972-EF39-4112-A6A0-100343A2FD09

P2093

Q34388544-07182403-C686-495F-B989-0E2307B45C76

Q34388544-4A5EAA21-94CF-4113-860F-AB2A4A5D5413

Q34388544-515C5E51-4058-4573-A4EA-0F4C8C67C57D

P275

Q34388544-478747F6-DD5D-4D1C-9B24-28AEE292CE97

P2860

Q34388544-0A804974-3C83-4520-8503-25FB58CF0B31

Q34388544-1C097BE6-712A-4772-A49C-C387AC11337F

Q34388544-236CACEE-C03D-4193-9E2C-BE4EFCD1E7C9

Q34388544-2DA4E60C-A553-412C-8ECB-CCA7073A3F79

Q34388544-3075DCF6-C7FE-49D2-B8F8-5E8E93323377

Q34388544-39D31D48-1990-44E2-B526-2272D592B331

Q34388544-490E5108-2651-4A63-8CC1-D451D6CBF36C

Q34388544-5B8C8A96-CE99-453D-B474-F1F8BADB01D9

Q34388544-7A8BE4AF-1A53-4464-84DA-E30892A77F87

Q34388544-ABD40199-F232-4DA1-BB27-95D5C5011949

P304

Q34388544-8E72A770-5C77-4677-A1D2-9BAD60A3C643

P31

Q34388544-433C21CB-9AE4-43C8-B1FE-498B78408B73

Q34388544-64A1649C-2BA3-436B-8610-F8DE581BEB9D

P356

Q34388544-2FBA269E-01E3-4BB9-8FF8-D84F56BD7891

P407

Q34388544-7FD28E6C-CF87-458E-BC62-57865530D4C8

P478

Q34388544-00271CAB-CAC3-4FA8-84BD-89AC02FBD433

P5008

Q34388544-DA4F8A5A-4D99-4973-8237-76A9AA4C54A0

P577

Q34388544-9D447BDD-CC61-4006-A29C-79718E0760A6

P5875

Q34388544-13F8FE35-4F47-444F-A0FB-9B435BA89727

P698

Q34388544-0A1339D9-ADF9-4830-BB1C-342AA5629E4E

P921

Q34388544-680D9DEE-DD0D-4E42-9950-ED2DE49BC669

Q34388544-6F240B90-C77B-432C-9CEB-5FCDF25A7E1F

Q34388544-AB49C7FA-8BC1-4440-B144-B1AAD22102B9

Q34388544-D5360099-3FB1-448A-B67D-178BB5561AE1

P932

Q34388544-B2DE0656-05D1-472C-BC54-D1889449A20F

P356

P1433

Drug Design, Development and Therapy

P1476

Canagliflozin: a novel treatment option for type 2 diabetes.

@en

P2093

Eric Dietrich

http://www.w3.org/2001/XMLSchema#string

James R Taylor

http://www.w3.org/2001/XMLSchema#string

Jason Powell

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Renal Na(+)-glucose cotransporters

SGLT2 inhibition--a novel strategy for diabetes treatment.

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose.

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.

P304

1399-1408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S48937

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258959341

http://www.w3.org/2001/XMLSchema#string

P698

24285921

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

heterocyclic compound

type-2 diabetes

maturity-onset diabetes of the young

P932

3840773

http://www.w3.org/2001/XMLSchema#string